如何将新冠病毒的知识转化为对奥密克戎变异株的预防。
How to translate the knowledge of COVID-19 into the prevention of Omicron variants.
作者信息
Wang Xiangdong, Powell Charles A
机构信息
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
出版信息
Clin Transl Med. 2021 Dec;11(12):e680. doi: 10.1002/ctm2.680.
Abstract
Omicron variants are part of the "Coronavirus disease 2019 [COVID-19] Variants of Concerns" and has the potential to spread around the world rapidly and can harm human life. We can anticipate that the endemic state of COVID-19 will be characterized by the development of new strains with surges that will predominate in unvaccinated and immunodeficient populations. Thus, there will be an important role in promoting vaccinations, boosters and accessible testing to prevent disease transmission and to rapidly detect surges. There is an urgent need to explore the virology and biology of Omicron variants, define clinical phenomes and therapies, monitor dynamics of genetic changes, and translate the knowledge of COVID-19 into new variants. Clinical and translational medicine will be impactful in addressing these challenges by providing new insights for understanding and predicting new variants-associated transmissibility, disease severity, immune escape, diagnostic or therapeutic failure.
摘要
奥密克戎变种是“2019冠状病毒病[COVID-19]关注变种”的一部分，有可能在全球迅速传播，并可能危害人类生命。我们可以预计，COVID-19的地方流行状态将以新毒株的出现为特征，这些毒株的激增将在未接种疫苗和免疫功能低下的人群中占主导地位。因此，在推广疫苗接种、加强针接种和可及的检测以预防疾病传播和快速检测激增情况方面将发挥重要作用。迫切需要探索奥密克戎变种的病毒学和生物学特性，确定临床表型和治疗方法，监测基因变化动态，并将COVID-19的知识转化为针对新变种的认识。临床和转化医学将通过提供新的见解来理解和预测与新变种相关的传播性、疾病严重程度、免疫逃逸、诊断或治疗失败，从而在应对这些挑战方面发挥重要作用。
相似文献
1
How to translate the knowledge of COVID-19 into the prevention of Omicron variants.如何将新冠病毒的知识转化为对奥密克戎变异株的预防。
Clin Transl Med. 2021 Dec;11(12):e680. doi: 10.1002/ctm2.680.
2
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
3
Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.奥密克戎变异株带来的挑战及应对策略。
J Microbiol Immunol Infect. 2022 Jun;55(3):387-394. doi: 10.1016/j.jmii.2022.03.007. Epub 2022 Apr 26.
4
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.与未接种疫苗的患者相比，使用主要生物标志物比较感染 SARS-CoV-2 Delta 或 Omicron VOC 患者的疾病严重程度和同源疫苗接种效果。
J Med Virol. 2022 Dec;94(12):5867-5876. doi: 10.1002/jmv.28098. Epub 2022 Sep 9.
5
Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains.奥密克戎变异株 SARS-CoV-2 感染可引起接受加强针或感染变异株人群的交叉保护免疫。
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221133001. doi: 10.1177/03946320221133001.
6
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529（奥密克戎）变异株-美国，2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
7
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.SARS-CoV-2 变异株的进化：对免疫逃逸、疫苗接种、治疗和诊断策略的影响。
Viruses. 2023 Apr 10;15(4):944. doi: 10.3390/v15040944.
8
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.奥密克戎 BA.1 含mRNA-1273 加强针与英国原始 COVID-19 疫苗的比较：一项随机、观察者盲、活性对照试验。
Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19.
9
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月，英国青少年在先前感染和接种疫苗后对 delta（B.1.617.2）和 omicron（B.1.1.529）BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用：一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
10
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
引用本文的文献
1
A novel deterioration prediction system for mild COVID-19 patients in Korea: a retrospective study.韩国一种新型的轻症 COVID-19 患者恶化预测系统：一项回顾性研究。
Sci Rep. 2024 Aug 30;14(1):20171. doi: 10.1038/s41598-024-71033-x.
2
Barriers and facilitators to COVID-19 testing among staff and parents from San Diego schools.圣地亚哥学校教职员工和家长进行 COVID-19 检测的障碍和促进因素。
BMC Public Health. 2023 Jun 5;23(1):1068. doi: 10.1186/s12889-023-15854-x.
3
COVID-19 Positive Status is Associated with Increased In-hospital Mortality in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis.新型冠状病毒肺炎阳性状态与急性心肌梗死患者院内死亡率增加相关：一项系统评价和荟萃分析
J Community Hosp Intern Med Perspect. 2022 Sep 9;12(4):17-24. doi: 10.55729/2000-9666.1103. eCollection 2022.
4
Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai.上海 1139 例奥密克戎变异株感染者的轻症临床特征。
J Med Virol. 2023 Jan;95(1):e28224. doi: 10.1002/jmv.28224. Epub 2022 Oct 26.
5
Current trends in COVID-19 diagnosis and its new variants in physiological fluids: Surface antigens, antibodies, nucleic acids, and RNA sequencing.COVID-19诊断的当前趋势及其在生理体液中的新变体：表面抗原、抗体、核酸和RNA测序。
Trends Analyt Chem. 2022 Dec;157:116750. doi: 10.1016/j.trac.2022.116750. Epub 2022 Aug 30.
6
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?奥密克戎变异株（B.1.1.529）及其亚谱系：在 SARS-CoV-2 重组变异株出现之际，我们目前了解多少？
Biomed Pharmacother. 2022 Oct;154:113522. doi: 10.1016/j.biopha.2022.113522. Epub 2022 Aug 15.
7
Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Case-Control Real-World Study.福建地区 SARS-CoV-2 突破感染预测的列线图模型：一项病例对照的真实世界研究。
Front Cell Infect Microbiol. 2022 Jun 23;12:932204. doi: 10.3389/fcimb.2022.932204. eCollection 2022.
8
Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19.利用生物信息学和系统生物学方法揭示COVID-19合并非小细胞肺癌患者的相互作用网络及治疗意义
Front Pharmacol. 2022 Jun 2;13:857730. doi: 10.3389/fphar.2022.857730. eCollection 2022.
9
The impact of the Omicron epidemic on the health behavior in Cape Town, South Africa.奥密克戎疫情对南非开普敦健康行为的影响。
One Health. 2022 May 5;14:100395. doi: 10.1016/j.onehlt.2022.100395. eCollection 2022 Jun.
10
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.德尔塔变异株（B.1.617.2）：SARS-CoV-2 的突变、影响、挑战及可能的解决方案。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2068883. doi: 10.1080/21645515.2022.2068883. Epub 2022 May 4.
本文引用的文献
1
A cellular census of human peripheral immune cells identifies novel cell states in lung diseases.人类外周免疫细胞的细胞普查鉴定出肺部疾病中的新型细胞状态。
Clin Transl Med. 2021 Nov;11(11):e579. doi: 10.1002/ctm2.579.
2
Accurate classification of COVID-19 patients with different severity via machine learning.通过机器学习对不同严重程度的新冠病毒疾病患者进行准确分类。
Clin Transl Med. 2021 Mar;11(3):e323. doi: 10.1002/ctm2.323.
3
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.人月经血间充质基质细胞治疗重症和危重症 COVID-19 患者的安全性和有效性评价：一项探索性临床试验。
Clin Transl Med. 2021 Feb;11(2):e297. doi: 10.1002/ctm2.297.
4
Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection.在新冠病毒感染低发国家的中高风险地区进行新冠疫苗的环状接种。
Clin Transl Med. 2021 Feb;11(2):e331. doi: 10.1002/ctm2.331.
5
Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis.恢复期血浆疗法治疗新冠肺炎患者的临床疗效：来自配对研究和荟萃分析的证据。
Clin Transl Med. 2020 Dec;10(8):e259. doi: 10.1002/ctm2.259.
6
CIRPMC: An online model with simplified inflammatory signature to predict the occurrence of critical illness in patients with COVID-19.CIRPMC：一种具有简化炎症特征的在线模型，用于预测COVID-19患者危重症的发生。
Clin Transl Med. 2020 Oct;10(6):e210. doi: 10.1002/ctm2.210.
7
The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19.新型冠状病毒肺炎患者外周免疫反应的非编码和编码转录图谱
Clin Transl Med. 2020 Oct;10(6):e200. doi: 10.1002/ctm2.200.
8
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.由弥漫性肺血栓和对溶栓有反应的肺内皮功能障碍驱动的COVID-19危重病病理生理学。
Clin Transl Med. 2020 Jun;10(2):e44. doi: 10.1002/ctm2.44. Epub 2020 Jun 5.
9
Significance of clinical phenomes of patients with COVID-19 infection: A learning from 3795 patients in 80 reports.新型冠状病毒肺炎感染患者临床表型的意义：来自80篇报告中3795例患者的经验教训
Clin Transl Med. 2020 Jan;10(1):28-35. doi: 10.1002/ctm2.17. Epub 2020 Apr 4.
10
Acute lung injury in patients with COVID-19 infection.新型冠状病毒肺炎（COVID-19）感染患者的急性肺损伤
Clin Transl Med. 2020 Jan;10(1):20-27. doi: 10.1002/ctm2.16. Epub 2020 Mar 31.
Zotero 插件